Abstract
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
| Original language | English |
|---|---|
| Pages (from-to) | 6088-6100 |
| Number of pages | 13 |
| Journal | Theranostics |
| Volume | 8 |
| Issue number | 22 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- Neuroendocrine tumor
- Peptide receptor radionuclide therapy
- PRRT
- Somatostatin receptor
- Theranostics
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Cite this
The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go? / Werner, Rudolf A.; Weich, Alexander; Kircher, Malte; Solnes, Lilja B.; Javadi, Mehrbod S.; Higuchi, Takahiro; Buck, Andreas K.; Pomper, Martin G.; Rowe, Steven P.; Lapa, Constantin.
In: Theranostics, Vol. 8, No. 22, 01.01.2018, p. 6088-6100.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?
AU - Werner, Rudolf A.
AU - Weich, Alexander
AU - Kircher, Malte
AU - Solnes, Lilja B.
AU - Javadi, Mehrbod S.
AU - Higuchi, Takahiro
AU - Buck, Andreas K.
AU - Pomper, Martin G.
AU - Rowe, Steven P.
AU - Lapa, Constantin
PY - 2018/1/1
Y1 - 2018/1/1
N2 - More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
AB - More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
KW - Neuroendocrine tumor
KW - Peptide receptor radionuclide therapy
KW - PRRT
KW - Somatostatin receptor
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85059303436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059303436&partnerID=8YFLogxK
U2 - 10.7150/thno.30357
DO - 10.7150/thno.30357
M3 - Review article
C2 - 30613284
AN - SCOPUS:85059303436
VL - 8
SP - 6088
EP - 6100
JO - Theranostics
JF - Theranostics
SN - 1838-7640
IS - 22
ER -